Moomoo AIのまとめ
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investment entities. Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, reported their respective holdings in Altimmune's common stock. NAM reported beneficial ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares, with all shares being acquired in the ordinary course of business. The combined holdings represent a total of 3.21% of Altimmune's common stock. The filing, dated February 14, 2024, confirms that the shares were not acquired with the intention of changing or influencing the control of Altimmune Inc. The principal executive offices of Altimmune Inc. are located at 910 Clopper Road, Suite 201S, Gaithersburg, MD, United States.
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investment entities. Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, reported their respective holdings in Altimmune's common stock. NAM reported beneficial ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares, with all shares being acquired in the ordinary course of business. The combined holdings represent a total of 3.21% of Altimmune's common stock. The filing, dated February 14, 2024, confirms that the shares were not acquired with the intention of changing or influencing the control of Altimmune Inc. The principal executive offices of Altimmune Inc. are located at 910 Clopper Road, Suite 201S, Gaithersburg, MD, United States.
2023年12月31日、バイオ医薬品企業のアルティミュンは、有力投資企業による所有権変更を示す証券取引委員会（SEC）のスケジュール13Gの提出対象となりました。デラウェアに本社を置くNuveen Asset Management、LLC（NAM）、TIAA-CREF Investment Management、LLC（TCIM）、およびTeachers Advisors、LLC（TAL）は、アルティミュンの普通株式をそれぞれ保有しており、いずれもビジネスの通常運転の中で取得されたものです。NAMは6,679株、TCIMは1,549,364株、TALは171,273株を報告し、それらの株はアル...すべて展開
2023年12月31日、バイオ医薬品企業のアルティミュンは、有力投資企業による所有権変更を示す証券取引委員会（SEC）のスケジュール13Gの提出対象となりました。デラウェアに本社を置くNuveen Asset Management、LLC（NAM）、TIAA-CREF Investment Management、LLC（TCIM）、およびTeachers Advisors、LLC（TAL）は、アルティミュンの普通株式をそれぞれ保有しており、いずれもビジネスの通常運転の中で取得されたものです。NAMは6,679株、TCIMは1,549,364株、TALは171,273株を報告し、それらの株はアルティミュンの普通株式の総計の3.21％に相当します。2024年2月14日付けの提出書によれば、これらの株はアルティミュンの支配または影響を変更するために取得されたものではありません。アルティミュンの主要執行事務所は、米国メリーランド州ゲイザースバーグの910 Clopper Road、Suite 201Sにあります。
役に立った
役に立たない